We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current FOLD market cap is 3B. The company's latest EPS is USD -0.5132 and P/E is -19.76.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 81.69M | 88.1M | 86.27M | 94.5M | 103.5M |
| Operating Income | -33.27M | -40.74M | -37.64M | -17.39M | -15.03M |
| Net Income | -33.29M | -55.87M | -52.93M | -43.23M | -21.58M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 182.24M | 260.89M | 305.51M | 329.23M | 399.36M |
| Operating Income | -304.04M | -247M | -206.43M | -204.43M | -73.49M |
| Net Income | -356.39M | -276.85M | -250.46M | -236.57M | -151.58M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 759.53M | 724.17M | 700.52M | 730.09M | 764.08M |
| Total Liabilities | 626.96M | 601.12M | 597.95M | 618.51M | 630.85M |
| Total Equity | 132.57M | 123.05M | 102.57M | 111.58M | 133.24M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 850.21M | 886.52M | 905.14M | 724.17M | 777.88M |
| Total Liabilities | 373.78M | 600.14M | 597.77M | 601.12M | 617.71M |
| Total Equity | 476.43M | 286.38M | 307.37M | 123.05M | 160.17M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -85.8M | -166.58M | -18.07M | -34.2M | -72.55M |
| Investing | 159.02M | 92.32M | 36.26M | 86.26M | 122.02M |
| Financing | -8.02M | -7.46M | -7.83M | 15.85M | 53.47M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -250.42M | -233.29M | -202.49M | -166.58M | -69.09M |
| Investing | 95.15M | -13.58M | 78.76M | 92.32M | 98.06M |
| Financing | 217.5M | 262.86M | 212.07M | -7.46M | 61.68M |
| Market Cap | 3B |
| Price to Earnings Ratio | -19.76 |
| Price to Sales Ratio | 7.5 |
| Price to Cash Ratio | 12.13 |
| Price to Book Ratio | 18.7 |
| Dividend Yield | - |
| Shares Outstanding | 295.38M |
| Average Volume (1 week) | 3.23M |
| Average Volume (1 Month) | 2.71M |
| 52 Week Change | -11.35% |
| 52 Week High | 14.57 |
| 52 Week Low | 9.70 |
| Spread (Intraday) | 0.01 (0.1%) |
| Company Name | Amicus Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.amicusrx.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
